You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePanitumumab
Accession NumberDB01269
TypeBiotech
GroupsApproved, Investigational
DescriptionPanitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Protein structureDb01269
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
Synonyms
ABX-EGF
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VectibixInjection, solution, concentrate20 mg/mlIntravenousAmgen Europe B.V.2007-12-03Not applicableEu
VectibixSolution100 mg/5mLIntravenousAmgen2006-10-10Not applicableUs
VectibixSolution200 mgIntravenousAmgenNot applicableNot applicableCanada
VectibixInjection, solution, concentrate20 mg/mlIntravenousAmgen Europe B.V.2007-12-03Not applicableEu
VectibixSolution200 mg/10mLIntravenousAmgen2006-10-10Not applicableUs
VectibixSolution400 mgIntravenousAmgenNot applicableNot applicableCanada
VectibixSolution400 mg/20mLIntravenousAmgen2006-10-10Not applicableUs
VectibixInjection, solution, concentrate20 mg/mlIntravenousAmgen Europe B.V.2007-12-03Not applicableEu
VectibixSolution100 mgIntravenousAmgen2008-05-27Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6A901E312A
CAS number339177-26-3
Pharmacology
IndicationFor the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
Structured Indications
PharmacodynamicsPanitumumab is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human Epidermal Growth Factor Receptor (EGFR). EGFR is a transmembrane glycoprotein that belongs to the subfamily of type I receptor tyrosine kinases. Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, including those of the colon and rectum. Interaction of EGFR with its normal ligands causes phosphorylation and activation of a series of intracellular proteins that will in turn regulate the transcription of genes involved with cellular growth and survival, motility, and prolieration. Signal transduction through EGFR leads to the activation of the wild type KRAS gene, but the presence of an activating somatic mutation of the KRAS gene within a cancer cell can result in the dysregulation of signaling pathways and resistance to EGFR inhibitor therapy.
Mechanism of actionPanitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.
TargetKindPharmacological actionActionsOrganismUniProt ID
Epidermal growth factor receptorProteinyes
suppressor
HumanP00533 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life7.5 days (range: 4-11 days)
Clearance
  • 4.9+/- 1.4 mL/kg/day [Following single-dose administrations of panitumumab as 1-hour infusions]
ToxicityPanitumumab was shown to cause skin, ocular and mucosal related toxicities in 90% of patients receiving panitumumab. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage, were reported.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Panitumumab Action PathwayDrug actionSMP00475
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Panitumumab.Approved
ALT-110The therapeutic efficacy of ALT-110 can be decreased when used in combination with Panitumumab.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Panitumumab.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Panitumumab is combined with Belimumab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panitumumab.Approved
CDX-110The therapeutic efficacy of CDX-110 can be decreased when used in combination with Panitumumab.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Panitumumab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Panitumumab.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Panitumumab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panitumumab.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Panitumumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Panitumumab.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Panitumumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Panitumumab.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Panitumumab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panitumumab.Approved, Vet Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Panitumumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Panitumumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Panitumumab.Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. [PubMed:14967460 ]
  2. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. [PubMed:11255078 ]
  3. Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014. [PubMed:18343240 ]
  4. Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13. [PubMed:17355997 ]
  5. Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. [PubMed:20481659 ]
External Links
ATC CodesL01XC08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentKRAS and NRAS Wild-type Colorectal Cancer1
1Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1CompletedNot AvailableTumors, Solid1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentOncology / Tumors / Tumors, Solid1
1, 2Active Not RecruitingTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
1, 2Active Not RecruitingTreatmentPancreatic Cancers1
1, 2CompletedNot AvailableMetastatic Colorectal Cancers1
1, 2CompletedTreatmentCancer of the Esophagus1
1, 2CompletedTreatmentCancers1
1, 2CompletedTreatmentColon Cancer / Colorectal Cancers / Gastrointestinal Cancers / Metastatic Colorectal Cancers / Rectal Cancers1
1, 2CompletedTreatmentColon Cancer / Colorectal Cancers / Metastatic Colorectal Cancers / Oncology / Rectal Cancers1
1, 2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
1, 2RecruitingTreatmentAnus / Epidermoid Carcinoma1
1, 2RecruitingTreatmentColorectal Cancers1
1, 2TerminatedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentEsophageal Adenocarcinomas / Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentAnal Squamous Cell Carcinoma1
2Active Not RecruitingTreatmentBiliary Cancer / Cholangiocarcinomas1
2Active Not RecruitingTreatmentCancer of Head / Cancer of Head and Neck / Cancer of Neck / Cancer of the Head / Cancer of the Neck / Cancers of the Head and Neck / Head and Neck Cancers / Head Cancer / Head, Neck Neoplasms / Neck Cancer / Neoplasms, Head / Neoplasms, Head and Neck / Neoplasms, Neck / Neoplasms, Upper Aerodigestive Tract / UADT Neoplasms1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentCancers / Carcinomas / Head and Neck Cancers / Metastases / Metastatic Cancers / Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck / Oncology / Squamous Cell Carcinoma (SCC) / Tumors1
2Active Not RecruitingTreatmentCholangiocarcinomas1
2Active Not RecruitingTreatmentColon Cancer / Colorectal Cancers / Metastatic Colorectal Cancers / Rectal Cancers1
2Active Not RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2Active Not RecruitingTreatmentGastroesophageal Junction Neoplasms / Stomach Neoplasms1
2Active Not RecruitingTreatmentMalignant Neoplasm of Esophagus / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers2
2Active Not RecruitingTreatmentRectal Cancers1
2Active Not RecruitingTreatmentStage IV Colorectal Cancer1
2CompletedTreatmentAdenocarcinomas / Esophageal Cancers / Gastro-esophageal Junction Cancer / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentAdvanced Head and Neck Squamous Cancer1
2CompletedTreatmentAdvanced Renal Cell Carcinoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma / Colorectal Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) / Prostate Cancers / Tumors, Solid1
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Cancer1
2CompletedTreatmentCancers / Colon Cancer / Colorectal Cancers / Metastatic Cancers / Metastatic Colorectal Cancers / Rectal Cancers1
2CompletedTreatmentCancers / Head and Neck Cancers / Oncology / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinomas / Colorectal Cancers1
2CompletedTreatmentColorectal Cancers4
2CompletedTreatmentColorectal Cancers / Liver Metastases1
2CompletedTreatmentColorectal Cancers / Metastases1
2CompletedTreatmentEpithelial Ovarian Cancer1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentHead and Neck Cancers / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentLung Cancers / Neoplasms Metastasis / Non-Small-Cell Lung Carcinoma (NSCLC)2
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Colo-rectal Cancer1
2CompletedTreatmentMetastatic Colorectal Cancers5
2CompletedTreatmentMetastatic or Recurrent Squamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
2CompletedTreatmentPathological Response Rate1
2CompletedTreatmentProstate Cancers1
2CompletedTreatmentSquamous Cell Carcinoma of Head and Neck1
2Not Yet RecruitingTreatmentBRAF Wildtype / Colorectal Cancers / KRAS Wildtype / NRAS Wildtype1
2Not Yet RecruitingTreatmentCancer, Breast1
2Not Yet RecruitingTreatmentColorectal Cancers1
2Not Yet RecruitingTreatmentHead and Neck Cancers1
2RecruitingTreatmentAfter Resection of Liver Metastases / Colorectal Cancers / KRAS Wildtype1
2RecruitingTreatmentCancer, Ovarian1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCholangiocarcinomas2
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentGastrointestinal Cancers1
2RecruitingTreatmentMetastatic Cancers1
2RecruitingTreatmentMetastatic Colorectal Cancers4
2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2SuspendedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentAdenocarcinoma of the Distal Esophagus / Adenocarcinoma of the Proximal Stomach / Adenocarcinomas of the Gastroesophageal Junction / Gastroesophageal Adenocarcinoma1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of Pancreas / Cancer of the Pancreas / Pancreas Cancer / Pancreatic Cancers1
2TerminatedTreatmentCarcinoma, Colorectal1
2TerminatedTreatmentIrresectable Squamous Cell or Adenocarcinoma of the Oesophagus1
2TerminatedTreatmentKRAS Wild Type / Resectable Type II Gastric Adenocarcinoma1
2TerminatedTreatmentMalignant Glioma of Brain1
2TerminatedTreatmentNeoplasms, Colorectal1
2TerminatedTreatmentNon Small Cell Lung Cancer (NSCLC)1
2TerminatedTreatmentRectal Cancers1
2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2TerminatedTreatmentUrinary Bladder Cancer1
2WithdrawnTreatmentAdenoma, Pleomorphic / Mixed Salivary Gland Tumor / Salivary Gland Tumor, Mixed / Syringoma, Chondroid1
2WithdrawnTreatmentCarcinoid Syndrome1
2WithdrawnTreatmentHead and Neck Cancers1
2WithdrawnTreatmentSalivary Gland Malignancy1
3Active Not RecruitingTreatmentEsophageal Squamous Cell Cancer1
3Active Not RecruitingTreatmentMetastatic Colorectal Cancers2
3CompletedTreatmentColorectal Cancers1
3CompletedTreatmentColorectal Cancers / Metastases1
3CompletedTreatmentMetastatic Colorectal Cancers2
3TerminatedTreatmentOesophago-gastric Cancer1
4RecruitingHealth Services ResearchColonic Cancers / Unresectable Metastasis Originating in Colonic Cancer1
4RecruitingTreatmentCancers1
Not AvailableCompletedNot AvailableAdvanced or Recurrent Colorectal Cancer1
Not AvailableCompletedNot AvailableMetastatic Colorectal Cancers1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous20 mg/ml
SolutionIntravenous100 mg/5mL
SolutionIntravenous100 mg
SolutionIntravenous200 mg/10mL
SolutionIntravenous200 mg
SolutionIntravenous400 mg/20mL
SolutionIntravenous400 mg
Prices
Unit descriptionCostUnit
Vectibix 400 mg/20ml Solution 20ml Vial4349.4USD vial
Vectibix 100 mg/5ml Solution 5ml Vial1059.24USD vial
Vectibix 100 mg/5 ml vial203.7USD ml
Vectibix 200 mg/10 ml vial203.7USD ml
Vectibix 400 mg/20 ml vial203.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
suppressor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on ke...
Gene Name:
EGFR
Uniprot ID:
P00533
Molecular Weight:
134276.185 Da
References
  1. Lynch DH, Yang XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002 Feb;29(1 Suppl 4):47-50. [PubMed:11894013 ]
  2. Cohen RB: Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003 Feb;2(4):246-51. [PubMed:12620146 ]
  3. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. [PubMed:14967460 ]
  4. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005 Sep;16(9):1425-33. Epub 2005 Jul 12. [PubMed:16012181 ]
  5. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R: Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4441s-4445s. [PubMed:16857825 ]
  6. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. [PubMed:11255078 ]
  7. Keating GM: Spotlight on panitumumab in metastatic colorectal cancer. BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000. [PubMed:20623992 ]
  8. Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014. [PubMed:18343240 ]
  9. Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13. [PubMed:17355997 ]
  10. Jean GW, Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. [PubMed:18503402 ]
  11. Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. [PubMed:20481659 ]
  12. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on May 16, 2007 14:12 / Updated on August 17, 2016 12:23